Claims for Patent: 7,153,490

Summary for Patent: 7,153,490

Title:	Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors
Abstract:	Liposomes encapsulating anticancerous drugs and the use thereof in the treatment of malignant tumors. The liposomes are coated with a lipopeptide composed of three substructures: a lipid fragment, an active oligopeptide and an oligopeptide spacer between the other two fragments. Applicable in intravenous administration for treatment of malignant tumors.
Inventor(s):	Parente Duena; Antonio (San Just Desvern, ES), Pons Lambiez; Ferran (Molins de Rei, ES), Fabra Fres; Angels (Barcelona, ES), Polo Trasancos; Maria Dolores (Barcelona, ES), Garces Garces; Josep (Martorell, ES), Reig Isart; Francesca (Barcelona, ES)
Assignee:	Lipotec, SA (ES)
Application Number:	10/398,627
Patent Claims:	1. A liposome encapsulating at least one anticancerous drug and coated with a lipopeptide composed of three substructures: a lipid fragment, a biologically active oligopeptide and an oligopeptide spacer between and bound to the lipid fragment and the active oligopeptide wherein the active oligopeptide is SEQ ID NO: 4 and the oligopeptide spacer is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. 2. The liposome of claim 1, wherein the lipid fragment of the lipopeptide comprises fatty acids of carbon chain length between C6 and C20. 3. The liposome of claim 1, wherein the lipid fragment of the lipopeptide comprises a lipid selected from the group consisting of: decanoyl, myristoyl and stearoyl. 4. The liposome of claim 1, wherein the oligopeptide spacer is SEQ ID NO: 1 bound to active oligopeptide SEQ ID NO: 4 to form SEQ ID NO: 5. 5. The liposome of claim 1, wherein the ratio of total lipids forming the liposome to the anticancerous drug is between 20:1 and 2:1. 6. The liposome of claim 1, wherein the ratio of total lipids forming the liposome to the anticancerous drug is 10:1. 7. The liposome of claim 1, wherein the lipid fragment comprises phospholipids, of both natural and synthetic origin, and cholesterol. 8. The liposome of claim 7, wherein the phospholipids present are a combination of neutral and negatively charged phospholipids. 9. The liposome of claim 8, wherein the neutral phospholipid is phosphatidylcholine. 10. The liposome of claim 8, wherein the negatively charged phospholipid is phosphatidylglycerol. 11. The liposome of claim 8, wherein the ratio of the neutral phospholipids to the negatively charged phospholipid is between 10:2 and 10:10. 12. The liposome of claim 8, wherein the ratio of the neutral phospholipids to the negatively charged phospholipid is between 10:7 and 10:10. 13. The liposome of claim 7, wherein the proportion of cholesterol, with respect to the total amount of lipids, is between 0 and 50%. 14. The liposome of claim 7, wherein the proportion of cholesterol, with respect to the total amount of lipids, is between 35 and 50%. 15. The liposome of claim 1 further containing at least one inhibitor of lipid peroxidation. 16. The liposome of claim 15, wherein the inhibitors of lipid peroxidation are Vitamins and their derivatives. 17. The liposome of claim 16, wherein the inhibitors of lipid peroxidation are selected from the group consisting of Vitamin E, Vitamin E acetate, BHT, chroman and chromen. 18. The liposome of claim 17, wherein the chromen is 3,4-dihydride-2,2-dimethyl-6-hydroxy-7-methoxy-2H-1-benzopyrane. 19. The liposome of claim 17, wherein the proportion of lipopeptide with respect to the total amount of lipids is between 0.1% and 30%. 20. The liposome of claim 19, wherein the proportion of lipopeptide with respect to the total amount of lipids is between 1% and 15%. 21. The liposome of claim 1, having an average size between 50 nm and 250 nm. 22. The liposome of claim 1, wherein the anticancerous drugs are selected from the group consisting of: nirogenated mustard analogues, cyclophosphamide, melphalan; phosphamide, trophosphamide, ethylenimines, thiotepa, nitrosoureas, carmustine, temozolomide, dacarbazine, antimetabolite analogues of folic acid, methotrexate, raltitrexed, purine analogues, thioguanine, cladribine, fludarabine, pyrimidine analogues, fluorouracil, florafur, gemcitabine, alkaloids of vinca or analogues thereof, vinblastine, vincristine, vinorelbine, podophyllotoxin derivatives, etoposide, taxanes, docetaxel, paclitaxel, anthracyclines, doxorubicin, epirubicin, idarubicin, mitoxantrone, cytotoxic antibiotics, bleomycin, mitomycin, platinum compounds, cisplatin, carboplatin and oxaliplatin, monoclonal antibodies, rituximab, pentostatin, miltefosine, estramustine, topotecan, irinotecan and bicalutamide. 23. A method of treating a malignant tumor in a mammal comprising administering intravenously to said mammal a pharmaceutically effective amount of the liposome of claim 1. 24. The method of claim 23, wherein said mammal is a human.

Details for Patent 7,153,490

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2020-10-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2020-10-10
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2020-10-10